3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Biliary Tract Neoplasms
2
Ovarian Neoplasms
1
HER2-expressing Cancers
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Malignancies
1
Interventions
Gemcitabine
34
Cisplatin
21
Capecitabine
18
Oxaliplatin
15
Leucovorin
10
Fluorouracil
10
Irinotecan
8
Erlotinib Hydrochloride
7
pembrolizumab
5
Bevacizumab
5
Radiotherapy
4
Carboplatin
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
Watchful Waiting
3
Taxes
3
Sorafenib
3
Platinum
3
Interleukin-12 Subunit p35
3
Immunohistochemistry
3
Docetaxel
3
1,2-diaminocyclohexaneplatinum II citrate
3
trifluridine tipiracil drug combination
2
tremelimumab
2
regorafenib
2
durvalumab
2
dehydroftorafur
2
Trastuzumab
2
Paclitaxel
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gallbladder Neoplasms
×
zanidatamab
×
Clear all
NCT04466891
2025-09-15
HERIZON-BTC-01
Jazz Pharmaceuticals
Phase 2
Completed
87 enrolled
25 charts
1 FDA